Iqvia (IQV) Releases Q1 Earnings Guidance

Iqvia (NYSE:IQV) updated its first quarter earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $1.23-1.30 for the period, compared to the Thomson Reuters consensus estimate of $1.20. Iqvia also updated its FY18 guidance to $5.35-5.60 EPS.

Several research firms have recently commented on IQV. SunTrust Banks reissued a hold rating and issued a $114.00 target price on shares of Iqvia in a research note on Friday, November 3rd. Jefferies Group raised their price target on Iqvia from $107.00 to $110.00 and gave the stock a hold rating in a research report on Monday, October 30th. Zacks Investment Research lowered Iqvia from a buy rating to a hold rating in a research report on Friday, November 3rd. Credit Suisse Group restated an outperform rating and issued a $125.00 price target (up from $115.00) on shares of Iqvia in a research report on Tuesday, October 31st. Finally, Barclays raised their price target on Iqvia from $100.00 to $120.00 and gave the stock an overweight rating in a research report on Friday, October 27th. Seven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Iqvia has an average rating of Buy and a consensus price target of $109.71.

Iqvia (NYSE IQV) opened at $104.68 on Thursday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.22 and a current ratio of 1.22. The firm has a market capitalization of $20,811.27, a PE ratio of 360.98, a price-to-earnings-growth ratio of 1.36 and a beta of 0.61. Iqvia has a twelve month low of $75.94 and a twelve month high of $110.67.

Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $1.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.34 by $0.06. The firm had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.14 billion. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.09 earnings per share. equities analysts predict that Iqvia will post 4.62 EPS for the current year.

In other news, insider James H. Erlinger III sold 10,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $99.97, for a total value of $999,700.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ari Bousbib sold 46,080 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $101.79, for a total value of $4,690,483.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,727,078 shares of company stock worth $890,124,079. Corporate insiders own 6.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://weekherald.com/2018/02/15/iqvia-iqv-releases-q1-earnings-guidance.html.

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply